nodes	percent_of_prediction	percent_of_DWPC	metapath
Zidovudine—ABCG2—Dactinomycin—muscle cancer	0.0934	0.129	CbGbCtD
Zidovudine—SLC22A11—Methotrexate—muscle cancer	0.0695	0.0958	CbGbCtD
Zidovudine—SLC22A7—Methotrexate—muscle cancer	0.0662	0.0913	CbGbCtD
Zidovudine—ABCC4—Methotrexate—muscle cancer	0.0647	0.0892	CbGbCtD
Zidovudine—ABCG2—Vincristine—muscle cancer	0.0575	0.0792	CbGbCtD
Zidovudine—ABCG2—Etoposide—muscle cancer	0.0527	0.0726	CbGbCtD
Zidovudine—SLC22A8—Methotrexate—muscle cancer	0.0404	0.0557	CbGbCtD
Zidovudine—ABCG2—Doxorubicin—muscle cancer	0.0359	0.0495	CbGbCtD
Zidovudine—ABCG2—Methotrexate—muscle cancer	0.0348	0.048	CbGbCtD
Zidovudine—ABCB1—Dactinomycin—muscle cancer	0.0337	0.0464	CbGbCtD
Zidovudine—SLC22A6—Methotrexate—muscle cancer	0.0282	0.0388	CbGbCtD
Zidovudine—CYP2C8—Etoposide—muscle cancer	0.0281	0.0387	CbGbCtD
Zidovudine—ALB—Methotrexate—muscle cancer	0.024	0.0331	CbGbCtD
Zidovudine—ABCB1—Vincristine—muscle cancer	0.0207	0.0286	CbGbCtD
Zidovudine—ABCB1—Etoposide—muscle cancer	0.019	0.0262	CbGbCtD
Zidovudine—ABCB1—Doxorubicin—muscle cancer	0.013	0.0178	CbGbCtD
Zidovudine—ABCB1—Methotrexate—muscle cancer	0.0126	0.0173	CbGbCtD
Zidovudine—CYP3A4—Vincristine—muscle cancer	0.0124	0.0171	CbGbCtD
Zidovudine—CYP3A4—Etoposide—muscle cancer	0.0114	0.0157	CbGbCtD
Zidovudine—CYP3A4—Doxorubicin—muscle cancer	0.00776	0.0107	CbGbCtD
Zidovudine—TK1—Validated targets of C-MYC transcriptional activation—PTMA—muscle cancer	0.00737	0.136	CbGpPWpGaD
Zidovudine—TERT—Validated targets of C-MYC transcriptional activation—PTMA—muscle cancer	0.00667	0.123	CbGpPWpGaD
Zidovudine—TERT—embryo—muscle cancer	0.00569	0.0986	CbGeAlD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.005	0.0923	CbGpPWpGaD
Zidovudine—SLC28A1—renal system—muscle cancer	0.00438	0.076	CbGeAlD
Zidovudine—TK1—E2F transcription factor network—TFE3—muscle cancer	0.0043	0.0794	CbGpPWpGaD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.00322	0.0595	CbGpPWpGaD
Zidovudine—TK1—E2F transcription factor network—TP73—muscle cancer	0.00291	0.0536	CbGpPWpGaD
Zidovudine—TERT—head—muscle cancer	0.00288	0.0499	CbGeAlD
Zidovudine—TERT—testis—muscle cancer	0.00278	0.0482	CbGeAlD
Zidovudine—TK1—tendon—muscle cancer	0.00231	0.0401	CbGeAlD
Zidovudine—TK1—bone marrow—muscle cancer	0.00224	0.0388	CbGeAlD
Zidovudine—SLC29A2—cardiac atrium—muscle cancer	0.00219	0.038	CbGeAlD
Zidovudine—TK1—vagina—muscle cancer	0.00215	0.0372	CbGeAlD
Zidovudine—TERT—Regulation of Telomerase—WT1—muscle cancer	0.00211	0.0389	CbGpPWpGaD
Zidovudine—TK1—head—muscle cancer	0.00198	0.0344	CbGeAlD
Zidovudine—TK1—testis—muscle cancer	0.00191	0.0332	CbGeAlD
Zidovudine—SLC29A2—tendon—muscle cancer	0.00191	0.0332	CbGeAlD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.00182	0.0336	CbGpPWpGaD
Zidovudine—SLC29A2—vagina—muscle cancer	0.00177	0.0308	CbGeAlD
Zidovudine—TK1—Validated targets of C-MYC transcriptional activation—HMGA1—muscle cancer	0.00169	0.0311	CbGpPWpGaD
Zidovudine—UGT2B7—renal system—muscle cancer	0.00165	0.0287	CbGeAlD
Zidovudine—SLC22A11—renal system—muscle cancer	0.00161	0.028	CbGeAlD
Zidovudine—SLC22A7—renal system—muscle cancer	0.00157	0.0273	CbGeAlD
Zidovudine—TERT—Validated targets of C-MYC transcriptional activation—HMGA1—muscle cancer	0.00152	0.0281	CbGpPWpGaD
Zidovudine—SLC22A2—renal system—muscle cancer	0.0014	0.0243	CbGeAlD
Zidovudine—ABCC5—cardiac atrium—muscle cancer	0.00118	0.0205	CbGeAlD
Zidovudine—UGT2B7—testis—muscle cancer	0.00107	0.0185	CbGeAlD
Zidovudine—ABCC5—tendon—muscle cancer	0.00103	0.0179	CbGeAlD
Zidovudine—SLC22A7—testis—muscle cancer	0.00102	0.0176	CbGeAlD
Zidovudine—ABCC5—bone marrow—muscle cancer	0.001	0.0173	CbGeAlD
Zidovudine—ABCC5—vagina—muscle cancer	0.000958	0.0166	CbGeAlD
Zidovudine—ABCC4—renal system—muscle cancer	0.000917	0.0159	CbGeAlD
Zidovudine—SLC22A8—renal system—muscle cancer	0.00091	0.0158	CbGeAlD
Zidovudine—CYP2A6—vagina—muscle cancer	0.000859	0.0149	CbGeAlD
Zidovudine—ABCC5—testis—muscle cancer	0.000855	0.0148	CbGeAlD
Zidovudine—TK1—Fluoropyrimidine Activity—TP53—muscle cancer	0.000773	0.0143	CbGpPWpGaD
Zidovudine—TK1—E2F transcription factor network—CDKN2A—muscle cancer	0.000736	0.0136	CbGpPWpGaD
Zidovudine—ABCC4—tendon—muscle cancer	0.000716	0.0124	CbGeAlD
Zidovudine—ABCC4—Ectoderm Differentiation—PAX3—muscle cancer	0.000713	0.0132	CbGpPWpGaD
Zidovudine—ABCC4—bone marrow—muscle cancer	0.000693	0.012	CbGeAlD
Zidovudine—CYP2C8—renal system—muscle cancer	0.000666	0.0115	CbGeAlD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.000618	0.0114	CbGpPWpGaD
Zidovudine—ABCC4—head—muscle cancer	0.000614	0.0106	CbGeAlD
Zidovudine—ALB—testis—muscle cancer	0.000612	0.0106	CbGeAlD
Zidovudine—SLC22A8—head—muscle cancer	0.000609	0.0106	CbGeAlD
Zidovudine—ABCC4—testis—muscle cancer	0.000593	0.0103	CbGeAlD
Zidovudine—CYP2C19—vagina—muscle cancer	0.000552	0.00958	CbGeAlD
Zidovudine—TERT—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000531	0.00981	CbGpPWpGaD
Zidovudine—ABCG2—bone marrow—muscle cancer	0.000489	0.00849	CbGeAlD
Zidovudine—CYP2C8—vagina—muscle cancer	0.000482	0.00836	CbGeAlD
Zidovudine—ABCG2—vagina—muscle cancer	0.000469	0.00813	CbGeAlD
Zidovudine—ABCC4—Ectoderm Differentiation—DMD—muscle cancer	0.000453	0.00836	CbGpPWpGaD
Zidovudine—CYP3A4—renal system—muscle cancer	0.000451	0.00782	CbGeAlD
Zidovudine—CYP2C8—testis—muscle cancer	0.00043	0.00746	CbGeAlD
Zidovudine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—muscle cancer	0.000426	0.00786	CbGpPWpGaD
Zidovudine—CYP2A6—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000423	0.00781	CbGpPWpGaD
Zidovudine—ABCB1—embryo—muscle cancer	0.000422	0.00731	CbGeAlD
Zidovudine—ABCG2—testis—muscle cancer	0.000418	0.00725	CbGeAlD
Zidovudine—Cardiac disorder—Etoposide—muscle cancer	0.00041	0.00253	CcSEcCtD
Zidovudine—Myalgia—Vincristine—muscle cancer	0.000404	0.00249	CcSEcCtD
Zidovudine—Mediastinal disorder—Etoposide—muscle cancer	0.000398	0.00246	CcSEcCtD
Zidovudine—Chills—Etoposide—muscle cancer	0.000397	0.00245	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000395	0.00244	CcSEcCtD
Zidovudine—Lymphadenopathy—Doxorubicin—muscle cancer	0.000388	0.00239	CcSEcCtD
Zidovudine—Oedema—Vincristine—muscle cancer	0.000388	0.00239	CcSEcCtD
Zidovudine—Anaphylactic shock—Vincristine—muscle cancer	0.000388	0.00239	CcSEcCtD
Zidovudine—Phlebitis—Doxorubicin—muscle cancer	0.000385	0.00237	CcSEcCtD
Zidovudine—TK1—Validated targets of C-MYC transcriptional activation—TP53—muscle cancer	0.000384	0.00709	CbGpPWpGaD
Zidovudine—Nervous system disorder—Vincristine—muscle cancer	0.00038	0.00234	CcSEcCtD
Zidovudine—Thrombocytopenia—Vincristine—muscle cancer	0.00038	0.00234	CcSEcCtD
Zidovudine—Decreased appetite—Dactinomycin—muscle cancer	0.000377	0.00233	CcSEcCtD
Zidovudine—Dysgeusia—Etoposide—muscle cancer	0.000377	0.00232	CcSEcCtD
Zidovudine—Hyperhidrosis—Vincristine—muscle cancer	0.000375	0.00231	CcSEcCtD
Zidovudine—Fatigue—Dactinomycin—muscle cancer	0.000374	0.00231	CcSEcCtD
Zidovudine—Back pain—Etoposide—muscle cancer	0.000372	0.00229	CcSEcCtD
Zidovudine—Pain—Dactinomycin—muscle cancer	0.000371	0.00229	CcSEcCtD
Zidovudine—Muscle spasms—Etoposide—muscle cancer	0.00037	0.00228	CcSEcCtD
Zidovudine—Anorexia—Vincristine—muscle cancer	0.00037	0.00228	CcSEcCtD
Zidovudine—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000365	0.00225	CcSEcCtD
Zidovudine—Irritability—Methotrexate—muscle cancer	0.000365	0.00225	CcSEcCtD
Zidovudine—Mood swings—Methotrexate—muscle cancer	0.000363	0.00224	CcSEcCtD
Zidovudine—Feeling abnormal—Dactinomycin—muscle cancer	0.000358	0.0022	CcSEcCtD
Zidovudine—Ill-defined disorder—Etoposide—muscle cancer	0.000357	0.0022	CcSEcCtD
Zidovudine—Anaemia—Etoposide—muscle cancer	0.000356	0.00219	CcSEcCtD
Zidovudine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000355	0.00219	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000353	0.00218	CcSEcCtD
Zidovudine—Insomnia—Vincristine—muscle cancer	0.000351	0.00216	CcSEcCtD
Zidovudine—Paraesthesia—Vincristine—muscle cancer	0.000348	0.00215	CcSEcCtD
Zidovudine—TERT—Validated targets of C-MYC transcriptional activation—TP53—muscle cancer	0.000348	0.00642	CbGpPWpGaD
Zidovudine—Malaise—Etoposide—muscle cancer	0.000347	0.00214	CcSEcCtD
Zidovudine—Breast disorder—Methotrexate—muscle cancer	0.000346	0.00213	CcSEcCtD
Zidovudine—Vertigo—Etoposide—muscle cancer	0.000346	0.00213	CcSEcCtD
Zidovudine—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000345	0.00212	CcSEcCtD
Zidovudine—Leukopenia—Etoposide—muscle cancer	0.000344	0.00212	CcSEcCtD
Zidovudine—Abdominal pain—Dactinomycin—muscle cancer	0.000343	0.00211	CcSEcCtD
Zidovudine—Body temperature increased—Dactinomycin—muscle cancer	0.000343	0.00211	CcSEcCtD
Zidovudine—Loss of consciousness—Etoposide—muscle cancer	0.000338	0.00209	CcSEcCtD
Zidovudine—Decreased appetite—Vincristine—muscle cancer	0.000337	0.00208	CcSEcCtD
Zidovudine—Cough—Etoposide—muscle cancer	0.000336	0.00207	CcSEcCtD
Zidovudine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.000336	0.00619	CbGpPWpGaD
Zidovudine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000335	0.00206	CcSEcCtD
Zidovudine—Fatigue—Vincristine—muscle cancer	0.000334	0.00206	CcSEcCtD
Zidovudine—Convulsion—Etoposide—muscle cancer	0.000333	0.00206	CcSEcCtD
Zidovudine—Constipation—Vincristine—muscle cancer	0.000332	0.00204	CcSEcCtD
Zidovudine—Pain—Vincristine—muscle cancer	0.000332	0.00204	CcSEcCtD
Zidovudine—ABCC4—Platelet degranulation—IGF2—muscle cancer	0.000331	0.00612	CbGpPWpGaD
Zidovudine—TK1—Metabolism—FH—muscle cancer	0.00033	0.0061	CbGpPWpGaD
Zidovudine—Chest pain—Etoposide—muscle cancer	0.000328	0.00202	CcSEcCtD
Zidovudine—Affect lability—Doxorubicin—muscle cancer	0.000326	0.00201	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000325	0.00201	CcSEcCtD
Zidovudine—Pancreatitis—Methotrexate—muscle cancer	0.000324	0.002	CcSEcCtD
Zidovudine—Discomfort—Etoposide—muscle cancer	0.000324	0.002	CcSEcCtD
Zidovudine—ABCB1—renal system—muscle cancer	0.000319	0.00553	CbGeAlD
Zidovudine—Gastrointestinal pain—Vincristine—muscle cancer	0.000317	0.00195	CcSEcCtD
Zidovudine—Confusional state—Etoposide—muscle cancer	0.000317	0.00195	CcSEcCtD
Zidovudine—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000316	0.00583	CbGpPWpGaD
Zidovudine—Pancytopenia—Methotrexate—muscle cancer	0.000314	0.00194	CcSEcCtD
Zidovudine—Anaphylactic shock—Etoposide—muscle cancer	0.000314	0.00194	CcSEcCtD
Zidovudine—Mood swings—Doxorubicin—muscle cancer	0.000314	0.00194	CcSEcCtD
Zidovudine—Asthenia—Dactinomycin—muscle cancer	0.000311	0.00192	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—KIDINS220—muscle cancer	0.00031	0.00572	CbGpPWpGaD
Zidovudine—Neutropenia—Methotrexate—muscle cancer	0.000309	0.00191	CcSEcCtD
Zidovudine—Dysuria—Methotrexate—muscle cancer	0.000309	0.00191	CcSEcCtD
Zidovudine—ABCC5—Fluoropyrimidine Activity—TP53—muscle cancer	0.000308	0.00568	CbGpPWpGaD
Zidovudine—Thrombocytopenia—Etoposide—muscle cancer	0.000308	0.0019	CcSEcCtD
Zidovudine—Body temperature increased—Vincristine—muscle cancer	0.000306	0.00189	CcSEcCtD
Zidovudine—Abdominal pain—Vincristine—muscle cancer	0.000306	0.00189	CcSEcCtD
Zidovudine—Skin disorder—Etoposide—muscle cancer	0.000305	0.00188	CcSEcCtD
Zidovudine—Hyperhidrosis—Etoposide—muscle cancer	0.000304	0.00187	CcSEcCtD
Zidovudine—Breast disorder—Doxorubicin—muscle cancer	0.000299	0.00185	CcSEcCtD
Zidovudine—Anorexia—Etoposide—muscle cancer	0.000299	0.00185	CcSEcCtD
Zidovudine—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000298	0.00184	CcSEcCtD
Zidovudine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000298	0.00184	CcSEcCtD
Zidovudine—Diarrhoea—Dactinomycin—muscle cancer	0.000297	0.00183	CcSEcCtD
Zidovudine—Nasopharyngitis—Doxorubicin—muscle cancer	0.000296	0.00183	CcSEcCtD
Zidovudine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000292	0.0018	CcSEcCtD
Zidovudine—TERT—Cell Cycle—BUB1B—muscle cancer	0.000292	0.00539	CbGpPWpGaD
Zidovudine—Stomatitis—Methotrexate—muscle cancer	0.000288	0.00177	CcSEcCtD
Zidovudine—Dysphagia—Doxorubicin—muscle cancer	0.000286	0.00177	CcSEcCtD
Zidovudine—Influenza—Doxorubicin—muscle cancer	0.000286	0.00177	CcSEcCtD
Zidovudine—ABCC5—Carbohydrate metabolism—ENO2—muscle cancer	0.000286	0.00527	CbGpPWpGaD
Zidovudine—Sweating—Methotrexate—muscle cancer	0.000283	0.00174	CcSEcCtD
Zidovudine—Paraesthesia—Etoposide—muscle cancer	0.000282	0.00174	CcSEcCtD
Zidovudine—Haematuria—Methotrexate—muscle cancer	0.000281	0.00173	CcSEcCtD
Zidovudine—Pancreatitis—Doxorubicin—muscle cancer	0.000281	0.00173	CcSEcCtD
Zidovudine—Dyspnoea—Etoposide—muscle cancer	0.00028	0.00173	CcSEcCtD
Zidovudine—Somnolence—Etoposide—muscle cancer	0.000279	0.00172	CcSEcCtD
Zidovudine—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000279	0.00515	CbGpPWpGaD
Zidovudine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000279	0.00172	CcSEcCtD
Zidovudine—Epistaxis—Methotrexate—muscle cancer	0.000278	0.00172	CcSEcCtD
Zidovudine—Asthenia—Vincristine—muscle cancer	0.000278	0.00171	CcSEcCtD
Zidovudine—Vomiting—Dactinomycin—muscle cancer	0.000276	0.0017	CcSEcCtD
Zidovudine—Agranulocytosis—Methotrexate—muscle cancer	0.000275	0.0017	CcSEcCtD
Zidovudine—Rash—Dactinomycin—muscle cancer	0.000274	0.00169	CcSEcCtD
Zidovudine—Decreased appetite—Etoposide—muscle cancer	0.000273	0.00168	CcSEcCtD
Zidovudine—Pancytopenia—Doxorubicin—muscle cancer	0.000272	0.00168	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000271	0.00167	CcSEcCtD
Zidovudine—Fatigue—Etoposide—muscle cancer	0.000271	0.00167	CcSEcCtD
Zidovudine—Pain—Etoposide—muscle cancer	0.000269	0.00166	CcSEcCtD
Zidovudine—Constipation—Etoposide—muscle cancer	0.000269	0.00166	CcSEcCtD
Zidovudine—Neutropenia—Doxorubicin—muscle cancer	0.000268	0.00165	CcSEcCtD
Zidovudine—Dysuria—Doxorubicin—muscle cancer	0.000268	0.00165	CcSEcCtD
Zidovudine—Diarrhoea—Vincristine—muscle cancer	0.000265	0.00164	CcSEcCtD
Zidovudine—Hepatitis—Methotrexate—muscle cancer	0.000265	0.00163	CcSEcCtD
Zidovudine—SLC22A7—Fluoropyrimidine Activity—TP53—muscle cancer	0.000265	0.00488	CbGpPWpGaD
Zidovudine—Pollakiuria—Doxorubicin—muscle cancer	0.000265	0.00163	CcSEcCtD
Zidovudine—Pharyngitis—Methotrexate—muscle cancer	0.000263	0.00162	CcSEcCtD
Zidovudine—Urinary tract disorder—Methotrexate—muscle cancer	0.000261	0.00161	CcSEcCtD
Zidovudine—Urethral disorder—Methotrexate—muscle cancer	0.00026	0.0016	CcSEcCtD
Zidovudine—Weight decreased—Doxorubicin—muscle cancer	0.000259	0.0016	CcSEcCtD
Zidovudine—Feeling abnormal—Etoposide—muscle cancer	0.000259	0.0016	CcSEcCtD
Zidovudine—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000258	0.00476	CbGpPWpGaD
Zidovudine—Nausea—Dactinomycin—muscle cancer	0.000258	0.00159	CcSEcCtD
Zidovudine—Gastrointestinal pain—Etoposide—muscle cancer	0.000257	0.00158	CcSEcCtD
Zidovudine—Dizziness—Vincristine—muscle cancer	0.000256	0.00158	CcSEcCtD
Zidovudine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000253	0.00156	CcSEcCtD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000252	0.00466	CbGpPWpGaD
Zidovudine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000252	0.00465	CbGpPWpGaD
Zidovudine—Erythema multiforme—Methotrexate—muscle cancer	0.00025	0.00154	CcSEcCtD
Zidovudine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00025	0.00154	CcSEcCtD
Zidovudine—Urticaria—Etoposide—muscle cancer	0.00025	0.00154	CcSEcCtD
Zidovudine—Stomatitis—Doxorubicin—muscle cancer	0.000249	0.00153	CcSEcCtD
Zidovudine—Jaundice—Doxorubicin—muscle cancer	0.000249	0.00153	CcSEcCtD
Zidovudine—Abdominal pain—Etoposide—muscle cancer	0.000248	0.00153	CcSEcCtD
Zidovudine—Body temperature increased—Etoposide—muscle cancer	0.000248	0.00153	CcSEcCtD
Zidovudine—Vomiting—Vincristine—muscle cancer	0.000247	0.00152	CcSEcCtD
Zidovudine—Cardiac disorder—Methotrexate—muscle cancer	0.000246	0.00152	CcSEcCtD
Zidovudine—Sweating—Doxorubicin—muscle cancer	0.000245	0.00151	CcSEcCtD
Zidovudine—Rash—Vincristine—muscle cancer	0.000244	0.00151	CcSEcCtD
Zidovudine—Dermatitis—Vincristine—muscle cancer	0.000244	0.00151	CcSEcCtD
Zidovudine—Haematuria—Doxorubicin—muscle cancer	0.000244	0.0015	CcSEcCtD
Zidovudine—Headache—Vincristine—muscle cancer	0.000243	0.0015	CcSEcCtD
Zidovudine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000242	0.00149	CcSEcCtD
Zidovudine—ABCB1—bone marrow—muscle cancer	0.000241	0.00418	CbGeAlD
Zidovudine—Epistaxis—Doxorubicin—muscle cancer	0.000241	0.00149	CcSEcCtD
Zidovudine—Sinusitis—Doxorubicin—muscle cancer	0.00024	0.00148	CcSEcCtD
Zidovudine—Mediastinal disorder—Methotrexate—muscle cancer	0.000239	0.00147	CcSEcCtD
Zidovudine—Agranulocytosis—Doxorubicin—muscle cancer	0.000238	0.00147	CcSEcCtD
Zidovudine—Chills—Methotrexate—muscle cancer	0.000238	0.00146	CcSEcCtD
Zidovudine—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000235	0.00434	CbGpPWpGaD
Zidovudine—Mental disorder—Methotrexate—muscle cancer	0.000232	0.00143	CcSEcCtD
Zidovudine—ABCB1—vagina—muscle cancer	0.000231	0.00401	CbGeAlD
Zidovudine—TERT—TGF-beta Signaling Pathway—TP53—muscle cancer	0.000231	0.00426	CbGpPWpGaD
Zidovudine—Erythema—Methotrexate—muscle cancer	0.000231	0.00142	CcSEcCtD
Zidovudine—Malnutrition—Methotrexate—muscle cancer	0.000231	0.00142	CcSEcCtD
Zidovudine—Nausea—Vincristine—muscle cancer	0.00023	0.00142	CcSEcCtD
Zidovudine—Rhinitis—Doxorubicin—muscle cancer	0.00023	0.00142	CcSEcCtD
Zidovudine—Hepatitis—Doxorubicin—muscle cancer	0.000229	0.00141	CcSEcCtD
Zidovudine—Pharyngitis—Doxorubicin—muscle cancer	0.000228	0.0014	CcSEcCtD
Zidovudine—Urinary tract disorder—Doxorubicin—muscle cancer	0.000226	0.0014	CcSEcCtD
Zidovudine—Dysgeusia—Methotrexate—muscle cancer	0.000226	0.00139	CcSEcCtD
Zidovudine—Asthenia—Etoposide—muscle cancer	0.000225	0.00139	CcSEcCtD
Zidovudine—Connective tissue disorder—Doxorubicin—muscle cancer	0.000225	0.00139	CcSEcCtD
Zidovudine—Urethral disorder—Doxorubicin—muscle cancer	0.000225	0.00139	CcSEcCtD
Zidovudine—Back pain—Methotrexate—muscle cancer	0.000223	0.00137	CcSEcCtD
Zidovudine—Pruritus—Etoposide—muscle cancer	0.000222	0.00137	CcSEcCtD
Zidovudine—Erythema multiforme—Doxorubicin—muscle cancer	0.000217	0.00134	CcSEcCtD
Zidovudine—Diarrhoea—Etoposide—muscle cancer	0.000215	0.00132	CcSEcCtD
Zidovudine—Ill-defined disorder—Methotrexate—muscle cancer	0.000214	0.00132	CcSEcCtD
Zidovudine—ABCB1—head—muscle cancer	0.000214	0.0037	CbGeAlD
Zidovudine—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	0.000213	0.00394	CbGpPWpGaD
Zidovudine—Anaemia—Methotrexate—muscle cancer	0.000213	0.00131	CcSEcCtD
Zidovudine—Cardiac disorder—Doxorubicin—muscle cancer	0.000213	0.00131	CcSEcCtD
Zidovudine—Malaise—Methotrexate—muscle cancer	0.000208	0.00128	CcSEcCtD
Zidovudine—Dizziness—Etoposide—muscle cancer	0.000208	0.00128	CcSEcCtD
Zidovudine—Vertigo—Methotrexate—muscle cancer	0.000207	0.00128	CcSEcCtD
Zidovudine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000207	0.00127	CcSEcCtD
Zidovudine—Leukopenia—Methotrexate—muscle cancer	0.000206	0.00127	CcSEcCtD
Zidovudine—ABCB1—testis—muscle cancer	0.000206	0.00358	CbGeAlD
Zidovudine—Chills—Doxorubicin—muscle cancer	0.000206	0.00127	CcSEcCtD
Zidovudine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.000202	0.00373	CbGpPWpGaD
Zidovudine—Cough—Methotrexate—muscle cancer	0.000201	0.00124	CcSEcCtD
Zidovudine—Mental disorder—Doxorubicin—muscle cancer	0.000201	0.00124	CcSEcCtD
Zidovudine—Convulsion—Methotrexate—muscle cancer	0.0002	0.00123	CcSEcCtD
Zidovudine—Vomiting—Etoposide—muscle cancer	0.0002	0.00123	CcSEcCtD
Zidovudine—Erythema—Doxorubicin—muscle cancer	0.0002	0.00123	CcSEcCtD
Zidovudine—Malnutrition—Doxorubicin—muscle cancer	0.0002	0.00123	CcSEcCtD
Zidovudine—Rash—Etoposide—muscle cancer	0.000198	0.00122	CcSEcCtD
Zidovudine—Dermatitis—Etoposide—muscle cancer	0.000198	0.00122	CcSEcCtD
Zidovudine—Headache—Etoposide—muscle cancer	0.000197	0.00121	CcSEcCtD
Zidovudine—Flatulence—Doxorubicin—muscle cancer	0.000197	0.00121	CcSEcCtD
Zidovudine—Myalgia—Methotrexate—muscle cancer	0.000196	0.00121	CcSEcCtD
Zidovudine—Chest pain—Methotrexate—muscle cancer	0.000196	0.00121	CcSEcCtD
Zidovudine—Arthralgia—Methotrexate—muscle cancer	0.000196	0.00121	CcSEcCtD
Zidovudine—Tension—Doxorubicin—muscle cancer	0.000196	0.00121	CcSEcCtD
Zidovudine—Dysgeusia—Doxorubicin—muscle cancer	0.000195	0.00121	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000195	0.0012	CcSEcCtD
Zidovudine—Discomfort—Methotrexate—muscle cancer	0.000194	0.0012	CcSEcCtD
Zidovudine—Nervousness—Doxorubicin—muscle cancer	0.000194	0.0012	CcSEcCtD
Zidovudine—Back pain—Doxorubicin—muscle cancer	0.000193	0.00119	CcSEcCtD
Zidovudine—Muscle spasms—Doxorubicin—muscle cancer	0.000192	0.00118	CcSEcCtD
Zidovudine—Confusional state—Methotrexate—muscle cancer	0.00019	0.00117	CcSEcCtD
Zidovudine—Anaphylactic shock—Methotrexate—muscle cancer	0.000188	0.00116	CcSEcCtD
Zidovudine—TK1—Metabolism—MED12—muscle cancer	0.000187	0.00345	CbGpPWpGaD
Zidovudine—Nausea—Etoposide—muscle cancer	0.000187	0.00115	CcSEcCtD
Zidovudine—Ill-defined disorder—Doxorubicin—muscle cancer	0.000185	0.00114	CcSEcCtD
Zidovudine—Nervous system disorder—Methotrexate—muscle cancer	0.000184	0.00114	CcSEcCtD
Zidovudine—Anaemia—Doxorubicin—muscle cancer	0.000184	0.00114	CcSEcCtD
Zidovudine—Thrombocytopenia—Methotrexate—muscle cancer	0.000184	0.00114	CcSEcCtD
Zidovudine—TERT—Disease—ENO2—muscle cancer	0.000184	0.00339	CbGpPWpGaD
Zidovudine—Skin disorder—Methotrexate—muscle cancer	0.000183	0.00113	CcSEcCtD
Zidovudine—Hyperhidrosis—Methotrexate—muscle cancer	0.000182	0.00112	CcSEcCtD
Zidovudine—Malaise—Doxorubicin—muscle cancer	0.00018	0.00111	CcSEcCtD
Zidovudine—Vertigo—Doxorubicin—muscle cancer	0.000179	0.00111	CcSEcCtD
Zidovudine—Anorexia—Methotrexate—muscle cancer	0.000179	0.00111	CcSEcCtD
Zidovudine—Syncope—Doxorubicin—muscle cancer	0.000179	0.0011	CcSEcCtD
Zidovudine—Leukopenia—Doxorubicin—muscle cancer	0.000179	0.0011	CcSEcCtD
Zidovudine—Loss of consciousness—Doxorubicin—muscle cancer	0.000175	0.00108	CcSEcCtD
Zidovudine—Cough—Doxorubicin—muscle cancer	0.000174	0.00107	CcSEcCtD
Zidovudine—Convulsion—Doxorubicin—muscle cancer	0.000173	0.00107	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000171	0.00106	CcSEcCtD
Zidovudine—TK1—Metabolism—ENO2—muscle cancer	0.00017	0.00314	CbGpPWpGaD
Zidovudine—Insomnia—Methotrexate—muscle cancer	0.00017	0.00105	CcSEcCtD
Zidovudine—Myalgia—Doxorubicin—muscle cancer	0.00017	0.00105	CcSEcCtD
Zidovudine—Arthralgia—Doxorubicin—muscle cancer	0.00017	0.00105	CcSEcCtD
Zidovudine—Chest pain—Doxorubicin—muscle cancer	0.00017	0.00105	CcSEcCtD
Zidovudine—Anxiety—Doxorubicin—muscle cancer	0.000169	0.00104	CcSEcCtD
Zidovudine—Paraesthesia—Methotrexate—muscle cancer	0.000169	0.00104	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000169	0.00104	CcSEcCtD
Zidovudine—Discomfort—Doxorubicin—muscle cancer	0.000168	0.00104	CcSEcCtD
Zidovudine—Dyspnoea—Methotrexate—muscle cancer	0.000168	0.00103	CcSEcCtD
Zidovudine—Somnolence—Methotrexate—muscle cancer	0.000167	0.00103	CcSEcCtD
Zidovudine—TERT—Disease—HMGA1—muscle cancer	0.000167	0.00308	CbGpPWpGaD
Zidovudine—Dyspepsia—Methotrexate—muscle cancer	0.000166	0.00102	CcSEcCtD
Zidovudine—Confusional state—Doxorubicin—muscle cancer	0.000164	0.00101	CcSEcCtD
Zidovudine—Decreased appetite—Methotrexate—muscle cancer	0.000164	0.00101	CcSEcCtD
Zidovudine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000163	0.001	CcSEcCtD
Zidovudine—Oedema—Doxorubicin—muscle cancer	0.000163	0.001	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000162	0.001	CcSEcCtD
Zidovudine—Fatigue—Methotrexate—muscle cancer	0.000162	0.001	CcSEcCtD
Zidovudine—Pain—Methotrexate—muscle cancer	0.000161	0.000992	CcSEcCtD
Zidovudine—Shock—Doxorubicin—muscle cancer	0.00016	0.000988	CcSEcCtD
Zidovudine—Nervous system disorder—Doxorubicin—muscle cancer	0.00016	0.000985	CcSEcCtD
Zidovudine—Thrombocytopenia—Doxorubicin—muscle cancer	0.000159	0.000983	CcSEcCtD
Zidovudine—Skin disorder—Doxorubicin—muscle cancer	0.000158	0.000975	CcSEcCtD
Zidovudine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000157	0.000971	CcSEcCtD
Zidovudine—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000156	0.00289	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—ANGPT2—muscle cancer	0.000156	0.00288	CbGpPWpGaD
Zidovudine—Anorexia—Doxorubicin—muscle cancer	0.000155	0.000957	CcSEcCtD
Zidovudine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000155	0.00286	CbGpPWpGaD
Zidovudine—Feeling abnormal—Methotrexate—muscle cancer	0.000155	0.000956	CcSEcCtD
Zidovudine—Gastrointestinal pain—Methotrexate—muscle cancer	0.000154	0.000948	CcSEcCtD
Zidovudine—ALB—Platelet degranulation—IGF2—muscle cancer	0.00015	0.00277	CbGpPWpGaD
Zidovudine—TERT—Disease—FOXO4—muscle cancer	0.00015	0.00276	CbGpPWpGaD
Zidovudine—Urticaria—Methotrexate—muscle cancer	0.000149	0.000921	CcSEcCtD
Zidovudine—Body temperature increased—Methotrexate—muscle cancer	0.000149	0.000917	CcSEcCtD
Zidovudine—Abdominal pain—Methotrexate—muscle cancer	0.000149	0.000917	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000148	0.000915	CcSEcCtD
Zidovudine—Insomnia—Doxorubicin—muscle cancer	0.000147	0.000908	CcSEcCtD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000147	0.00271	CbGpPWpGaD
Zidovudine—Paraesthesia—Doxorubicin—muscle cancer	0.000146	0.000902	CcSEcCtD
Zidovudine—Dyspnoea—Doxorubicin—muscle cancer	0.000145	0.000895	CcSEcCtD
Zidovudine—Somnolence—Doxorubicin—muscle cancer	0.000145	0.000893	CcSEcCtD
Zidovudine—Dyspepsia—Doxorubicin—muscle cancer	0.000143	0.000884	CcSEcCtD
Zidovudine—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000143	0.00264	CbGpPWpGaD
Zidovudine—CYP2A6—Fluoropyrimidine Activity—TP53—muscle cancer	0.000142	0.00262	CbGpPWpGaD
Zidovudine—Decreased appetite—Doxorubicin—muscle cancer	0.000142	0.000873	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000141	0.000867	CcSEcCtD
Zidovudine—Fatigue—Doxorubicin—muscle cancer	0.00014	0.000866	CcSEcCtD
Zidovudine—Constipation—Doxorubicin—muscle cancer	0.000139	0.000859	CcSEcCtD
Zidovudine—Pain—Doxorubicin—muscle cancer	0.000139	0.000859	CcSEcCtD
Zidovudine—ABCC4—Platelet degranulation—VEGFA—muscle cancer	0.000139	0.00257	CbGpPWpGaD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000136	0.00252	CbGpPWpGaD
Zidovudine—Asthenia—Methotrexate—muscle cancer	0.000135	0.000832	CcSEcCtD
Zidovudine—Feeling abnormal—Doxorubicin—muscle cancer	0.000134	0.000828	CcSEcCtD
Zidovudine—TERT—Cell Cycle—CDKN2A—muscle cancer	0.000133	0.00246	CbGpPWpGaD
Zidovudine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000133	0.000821	CcSEcCtD
Zidovudine—Pruritus—Methotrexate—muscle cancer	0.000133	0.000821	CcSEcCtD
Zidovudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.000132	0.00244	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—FH—muscle cancer	0.000132	0.00243	CbGpPWpGaD
Zidovudine—TERT—Cell Cycle—MDM2—muscle cancer	0.000129	0.00239	CbGpPWpGaD
Zidovudine—Urticaria—Doxorubicin—muscle cancer	0.000129	0.000798	CcSEcCtD
Zidovudine—Abdominal pain—Doxorubicin—muscle cancer	0.000129	0.000794	CcSEcCtD
Zidovudine—Body temperature increased—Doxorubicin—muscle cancer	0.000129	0.000794	CcSEcCtD
Zidovudine—Diarrhoea—Methotrexate—muscle cancer	0.000129	0.000794	CcSEcCtD
Zidovudine—Dizziness—Methotrexate—muscle cancer	0.000124	0.000767	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—PTCH1—muscle cancer	0.000122	0.00225	CbGpPWpGaD
Zidovudine—Vomiting—Methotrexate—muscle cancer	0.00012	0.000737	CcSEcCtD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000119	0.00219	CbGpPWpGaD
Zidovudine—Rash—Methotrexate—muscle cancer	0.000119	0.000731	CcSEcCtD
Zidovudine—Dermatitis—Methotrexate—muscle cancer	0.000119	0.000731	CcSEcCtD
Zidovudine—Headache—Methotrexate—muscle cancer	0.000118	0.000727	CcSEcCtD
Zidovudine—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000117	0.00216	CbGpPWpGaD
Zidovudine—Asthenia—Doxorubicin—muscle cancer	0.000117	0.000721	CcSEcCtD
Zidovudine—Pruritus—Doxorubicin—muscle cancer	0.000115	0.000711	CcSEcCtD
Zidovudine—Nausea—Methotrexate—muscle cancer	0.000112	0.000689	CcSEcCtD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000112	0.00206	CbGpPWpGaD
Zidovudine—Diarrhoea—Doxorubicin—muscle cancer	0.000111	0.000687	CcSEcCtD
Zidovudine—TERT—Disease—FOXO1—muscle cancer	0.000111	0.00204	CbGpPWpGaD
Zidovudine—Dizziness—Doxorubicin—muscle cancer	0.000108	0.000664	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—FOXO4—muscle cancer	0.000105	0.00194	CbGpPWpGaD
Zidovudine—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000104	0.00193	CbGpPWpGaD
Zidovudine—Vomiting—Doxorubicin—muscle cancer	0.000104	0.000639	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—CNR1—muscle cancer	0.000103	0.0019	CbGpPWpGaD
Zidovudine—Rash—Doxorubicin—muscle cancer	0.000103	0.000633	CcSEcCtD
Zidovudine—Dermatitis—Doxorubicin—muscle cancer	0.000103	0.000633	CcSEcCtD
Zidovudine—Headache—Doxorubicin—muscle cancer	0.000102	0.000629	CcSEcCtD
Zidovudine—UGT2B7—Metabolism—FH—muscle cancer	9.7e-05	0.00179	CbGpPWpGaD
Zidovudine—Nausea—Doxorubicin—muscle cancer	9.68e-05	0.000597	CcSEcCtD
Zidovudine—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	9.52e-05	0.00176	CbGpPWpGaD
Zidovudine—TERT—Disease—KIT—muscle cancer	8.43e-05	0.00156	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—IGF2—muscle cancer	8.42e-05	0.00155	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	8.16e-05	0.00151	CbGpPWpGaD
Zidovudine—ABCC5—Disease—ENO2—muscle cancer	8.09e-05	0.00149	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—FOXO1—muscle cancer	7.75e-05	0.00143	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—IGF2—muscle cancer	7.58e-05	0.0014	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—MED12—muscle cancer	7.43e-05	0.00137	CbGpPWpGaD
Zidovudine—TERT—Cell Cycle—TP53—muscle cancer	7.43e-05	0.00137	CbGpPWpGaD
Zidovudine—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	7.4e-05	0.00137	CbGpPWpGaD
Zidovudine—ABCC5—Disease—HMGA1—muscle cancer	7.35e-05	0.00136	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—ANGPT2—muscle cancer	7.05e-05	0.0013	CbGpPWpGaD
Zidovudine—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	6.96e-05	0.00128	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—ENO2—muscle cancer	6.78e-05	0.00125	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—FH—muscle cancer	6.69e-05	0.00123	CbGpPWpGaD
Zidovudine—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	6.65e-05	0.00123	CbGpPWpGaD
Zidovudine—TERT—Disease—MDM2—muscle cancer	6.64e-05	0.00123	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—FH—muscle cancer	6.62e-05	0.00122	CbGpPWpGaD
Zidovudine—ABCC5—Disease—FOXO4—muscle cancer	6.59e-05	0.00122	CbGpPWpGaD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	6.43e-05	0.00119	CbGpPWpGaD
Zidovudine—TERT—Disease—PTGS2—muscle cancer	6.4e-05	0.00118	CbGpPWpGaD
Zidovudine—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	6.38e-05	0.00118	CbGpPWpGaD
Zidovudine—ALB—Platelet degranulation—VEGFA—muscle cancer	6.29e-05	0.00116	CbGpPWpGaD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	6.16e-05	0.00114	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—FH—muscle cancer	6.07e-05	0.00112	CbGpPWpGaD
Zidovudine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	5.99e-05	0.00111	CbGpPWpGaD
Zidovudine—TK1—Metabolism—PTGS2—muscle cancer	5.93e-05	0.00109	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—KIT—muscle cancer	5.9e-05	0.00109	CbGpPWpGaD
Zidovudine—ABCB1—Allograft Rejection—VEGFA—muscle cancer	5.57e-05	0.00103	CbGpPWpGaD
Zidovudine—ALB—Folate Metabolism—TP53—muscle cancer	5.54e-05	0.00102	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—MED12—muscle cancer	5.48e-05	0.00101	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.26e-05	0.000971	CbGpPWpGaD
Zidovudine—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.23e-05	0.000966	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—ENO2—muscle cancer	4.99e-05	0.000922	CbGpPWpGaD
Zidovudine—SLC22A2—Neuronal System—MDM2—muscle cancer	4.89e-05	0.000902	CbGpPWpGaD
Zidovudine—ABCC5—Disease—FOXO1—muscle cancer	4.87e-05	0.000899	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.7e-05	0.000867	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—MDM2—muscle cancer	4.65e-05	0.000858	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.28e-05	0.000791	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—FH—muscle cancer	4.15e-05	0.000766	CbGpPWpGaD
Zidovudine—ALB—Metabolism—FH—muscle cancer	4.13e-05	0.000761	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—MED12—muscle cancer	3.78e-05	0.000697	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—MED12—muscle cancer	3.74e-05	0.00069	CbGpPWpGaD
Zidovudine—ABCC5—Disease—KIT—muscle cancer	3.71e-05	0.000685	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—FH—muscle cancer	3.7e-05	0.000683	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.62e-05	0.000668	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—FH—muscle cancer	3.61e-05	0.000667	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—VEGFA—muscle cancer	3.53e-05	0.000652	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.49e-05	0.000644	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—ENO2—muscle cancer	3.44e-05	0.000636	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—MED12—muscle cancer	3.43e-05	0.000633	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—IGF2—muscle cancer	3.43e-05	0.000633	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—ENO2—muscle cancer	3.41e-05	0.000629	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—FH—muscle cancer	3.38e-05	0.000623	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—VEGFA—muscle cancer	3.18e-05	0.000586	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—ENO2—muscle cancer	3.13e-05	0.000577	CbGpPWpGaD
Zidovudine—ABCC5—Disease—MDM2—muscle cancer	2.92e-05	0.000539	CbGpPWpGaD
Zidovudine—ABCC5—Disease—PTGS2—muscle cancer	2.82e-05	0.00052	CbGpPWpGaD
Zidovudine—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.79e-05	0.000515	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.75e-05	0.000507	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—TP53—muscle cancer	2.67e-05	0.000492	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—TP53—muscle cancer	2.4e-05	0.000443	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—PTGS2—muscle cancer	2.36e-05	0.000436	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—MED12—muscle cancer	2.34e-05	0.000433	CbGpPWpGaD
Zidovudine—ALB—Metabolism—MED12—muscle cancer	2.33e-05	0.00043	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—FH—muscle cancer	2.23e-05	0.000411	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—ENO2—muscle cancer	2.14e-05	0.000394	CbGpPWpGaD
Zidovudine—ALB—Metabolism—ENO2—muscle cancer	2.13e-05	0.000392	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—MED12—muscle cancer	2.09e-05	0.000386	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.08e-05	0.000383	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—MED12—muscle cancer	2.04e-05	0.000377	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—MED12—muscle cancer	1.91e-05	0.000352	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—ENO2—muscle cancer	1.91e-05	0.000352	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—ENO2—muscle cancer	1.86e-05	0.000344	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—PTGS2—muscle cancer	1.74e-05	0.000321	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—ENO2—muscle cancer	1.74e-05	0.000321	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.67e-05	0.000308	CbGpPWpGaD
Zidovudine—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.66e-05	0.000307	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.49e-05	0.000275	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—VEGFA—muscle cancer	1.44e-05	0.000265	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.36e-05	0.000251	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—MED12—muscle cancer	1.26e-05	0.000232	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—PTGS2—muscle cancer	1.2e-05	0.000221	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—PTGS2—muscle cancer	1.19e-05	0.000219	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—ENO2—muscle cancer	1.15e-05	0.000212	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—PTGS2—muscle cancer	1.09e-05	0.000201	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—TP53—muscle cancer	1.09e-05	0.000201	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—PTGS2—muscle cancer	7.44e-06	0.000137	CbGpPWpGaD
Zidovudine—ALB—Metabolism—PTGS2—muscle cancer	7.4e-06	0.000137	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—PTGS2—muscle cancer	6.64e-06	0.000123	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—PTGS2—muscle cancer	6.49e-06	0.00012	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—PTGS2—muscle cancer	6.06e-06	0.000112	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—PTGS2—muscle cancer	4e-06	7.37e-05	CbGpPWpGaD
